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Purpose
Juvenile Arthritis Disease Activity Score (JADAS) is a
recently developed composite tool for scoring disease
activity in juvenile idiopathic arthritis (JIA). JADAS con-
sists of four items; the joint count, the physician and the
patient’s/parent’s global assessment and the erythrocyte
sedimentation rate (ESR) as an inflammatory marker.
C-reactive protein (CRP) is often a more rapid and
available test than ESR and has been suggested as an
alternative inflammatory marker. The aim of the study
was to validate and compare the CRP versus the ESR as
an inflammatory marker in JADAS and to test whether
higher JADAS scores were associated to DMARD treat-
ment in a cohort of Nordic children with JIA in a near
population-based setting.
Methods
We included 514 consecutive cases of JIA from defined
geographical areas of Denmark, Finland, Sweden and
Norway with disease onset in 1997 to 2000. Clinical data
and disease activity measures were registered according to
a set protocol at regular follow-up visits from six to
147 months after onset. To calculate the JADAS, CRP was
“normalized” to a value in the range 0-10 in a similar
method as ESR, as described by Consolaro et al (1).
Cut-off for CRP was <10mg/ml and for ESR <20mm/H.
Spearman’s rank order correlation rho was used to evalu-
ate the correlations between CRP and ESR, and the
JADAS27 based on CRP and ESR. Logistic regression was
used to test the first JADAS score available as a predictor
of DMARD treatment, and whether mean JADAS score
was associated to treatment with methotrexate and biolo-
gic agents in children with at least three JADAS scores
available.
Results
Of the 514 children 66% were girls, 51% had oligoarticular
disease six months after onset and 3% were rheumatoid
factor positive. The first visit when both CRP and ESR
were taken was chosen for analysis. Correlation between
corresponding CRP and ESR values from each visit was
moderate (r= 0.57). There was a high correlation between
JADAS27-CRP versus JADAS27-ESR (r=0.98). Bland-
Altman plot of JADAS27-CRP versus JADAS27-ESR
showed a high level of agreement (mean difference of
0.046 (CI -0.012 to 0.104)). Higher score of the first avail-
able JADAS27-CRP was significantly associated to treat-
ment with methotrexate (OR= 1.12, 95%CI 1.07-1.17) and
synthetic or biologic DMARDs (OR= 1.16, 95%CI 1.10-
1.22) during the eight years follow-up after disease onset.
Mean JADAS27-CRP also showed a significant association
to treatment with methotrexate (OR= 1.37, 95%CI 1.19-
1.57) and synthetic or biologic DMARDs (OR= 1.64, 95%
CI 1.32-2.04) during the eight years follow-up after disease
onset.
Conclusion
JADAS based on CRP showed a high correlation with
JADAS based on ESR in a multi-center Nordic cohort of
juvenile idiopathic arthritis, indicating that CRP can be
used as an alternative to ESR in the composite tool.
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High mean JADAS score during disease course was sig-
nificantly associated to DMARD treatment in a prospec-
tive, longitudinal, multi-center Nordic JIA cohort.
Further analyses on responsiveness to change of the
JADAS-CRP are planned.
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